Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 13/20 | 1.00 |
| ▸ | PRKACA | P17612 | 11/20 | 1.00 |
| ▸ | GSK3B | P49841 | 11/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 10/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401655 | 0.94 | RPS6KB1 (1.00) | RPS6KB1PRKACAGSK3BROCK1RPS6KA5 | |
| SCHEMBL6407241 | 0.88 | RPS6KB1 (0.84) | RPS6KB1PRKACAGSK3BROCK1RPS6KA5 | |
| SCHEMBL4714279 | 0.84 | RPS6KA5 (1.00) | RPS6KB1PRKACAGSK3BROCK1RPS6KA5 | |
| SCHEMBL4716563 | 0.83 | RPS6KA5 (0.98) | RPS6KB1PRKACAGSK3BROCK1RPS6KA5 | |
| SCHEMBL4717559 | 0.81 | RPS6KA5 (0.93) | RPS6KB1PRKACAGSK3BROCK1RPS6KA5 | |
| SCHEMBL4718814 | 0.78 | RPS6KA5 (1.00) | RPS6KB1PRKACAGSK3BROCK1RPS6KA5 | |
| SCHEMBL6403535 | 0.78 | RPS6KB1 (0.66) | RPS6KB1PRKACAGSK3BROCK1RPS6KA5 | |
| SCHEMBL31267414 | 0.76 | RPS6KB1 (0.62) | RPS6KB1PRKACAGSK3BROCK1 | |
| SCHEMBL6402982 | 0.76 | RPS6KB1 (1.00) | RPS6KB1PRKACAGSK3BROCK1RPS6KA5 | |
| SCHEMBL28236159 | 0.76 | CYP11B2 (0.63) | RPS6KB1PRKACAGSK3BROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153978-A1 | Medicaments | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1487441-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080125-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153978-A1 | Medicaments | GRK1, ROCK1, GRK7 | RPS6KB1 63/4885PRKACA 595/4885GSK3B 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.